Global High Potency Active Pharmaceutical Ingredients (API) Market size was valued at USD 12.0 billion in 2014. Growing prevalence rate of cancer coupled with rising need for target-specific cytotoxic therapeutics is expected to boost demand in the near future. The growing number of pharmaceutical & biotech industry and increasing investments pertinent to R&D in emerging countries such as Asia-Pacific and Latin America regions are key factors expected to provide a growth platform to this industry over the forecast period.
Increasing global prevalence of cancer is expected to drive the High Potency Active Pharmaceutical Ingredients (API) market over the forecast period. Major side effect of chemotherapy is that it also affects noncancerous cells hence; targeted therapy is preferred and attributes to the rising demand over the forecast period.
In addition, the use of this product as an antibody drug conjugates (ADCs) is expected to improve penetration rates. Other diseases targeted by pharmaceutical companies in the development of high potency drugs include hormonal imbalance, glaucoma, and cardiovascular diseases. The presence of Government reforms such Patient Protection and Affordable Care Act in the U.S. helps in building the road map for the development of efficient drugs over the forecast period.
North America HPAPI market, by product, 2012-2022 (USD Million)
Synthetic and biotech products are two major segments analyzed in this study. Synthetic molecules dominated the overall market in 2014 with revenue share estimates at over 75.0%, owing to, the higher availability of raw material and easier protocols for synthesis of these molecules. The biotech segment is expected to witness lucrative growth owing to the introduction of technological advancements exhibiting high efficacy rates.
Manufacturers based HPAPI market is segmented into in-house and outsourced segments. The in-house segment dominated the overall industry in 2014 in terms of revenue at over 70% owing to the higher availability of raw material and intensive capitalization of major key players in the development of high-end manufacturing facilities. The contract manufacturing or outsourced segment is likely to rapidly gain demand owing to, the improving business infrastructure in emerging countries such as India and China.
Drug Type Insights
HPAPI drugs are classified as innovative and generic. Innovative drugs dominated the overall segment in 2014 in terms of revenue share at over 75% owing to the increasing R&D initiatives for novel drug development and favorable government regulations. Expiration of patents of branded drug molecules is expected to increase the growth of generic drugs over the forecast period.
Therapeutic Application Insights
HPAPIs are used mainly in the treatment of oncology, hormonal imbalance, glaucoma and others. Oncology treatment dominated the overall industry in 2014 in terms of revenue owing to the increasing prevalence of cancer worldwide. Hormonal segment followed oncology owing to rising cases of hormonal imbalance mainly in the female population. The disorders include thyroid and sexual hormone imbalance.
Global HPAPI market for branded drugs is expected to show lucrative growth over the forecast period, owing to rising target population worldwide coupled with increasing demand for fast acting and higher efficacy drugs. North America dominated the overall industry in terms of revenue in 2014 at over 40%.
A Higher level of awareness pertaining to highly potent drugs, increasing demand for anti-cancerous therapeutics and growing biotechnology industry is the factors attributing to a dominant share of this region. Asia Pacific, on the other hand, is expected to register lucrative growth over the forecast period owing to the flourishing generic drug market coupled with continuously developing healthcare infrastructure and presence of untapped opportunities.
Market Share Insights
The key players of the HPAPI market include Eli Lilly and Company, Novartis International AG, Bristol-Myers Squibb, Roche Diagnostics., Pfizer Inc., Hospira Inc, BASF AG, Covidien Plc, Boehringer Ingelheim, Merck & Co, Sigma-Aldrich Corporation, Bayer AG, Carbogen Amcis AG, Lonza, Teva Pharmaceutical Industries Ltd and Sanofi Aventis.
The market for branded drugs is consolidated with key players involved in intense competition and rivalry. Generics are expected to boost industrial growth. In addition, post patent expiration, mergers, acquisitions and collaborations activities, geographic expansion are expected to keep industry rivalry at higher levels over the forecast period.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.